The donor blood components market size is projected to reach US$ 14.64 billion by 2031 from US$ 10.08 billion in 2024. The market is expected to register a CAGR of 5.7% during 2025–2031. The rising demand for plasma-derived therapies is likely to bring in new market trends during the forecast period.
The donor blood components market is one of the prominent segments of the healthcare industry, driven by the increasing need for safe transfusions during surgery, trauma, cancer treatment, and chronic disease. Donor blood components include red blood cells (RBCs), plasma, platelets, and cryoprecipitate. The donor blood components market growth is being propelled by rising global awareness, aging populations, and growing advancements in collection and storage technologies. However, issues such as low rates of voluntary donations in certain regions, regulatory issues, and logistical limitations remain. New technologies such as apheresis and pathogen reduction systems are improving product safety and efficiency. Furthermore, government and NGO initiatives to increase regular, voluntary blood donation are increasing the donor base. The market has great potential, particularly in evolving healthcare systems.
The donor blood components market is rapidly expanding due to the rising prevalence of cancer and immunosuppressive diseases, and increasing donor awareness. Prominent players operating in the market are focusing on innovations and collaborative efforts for enhanced product availability and reach. However, the inconsistent voluntary donations hinder market growth.
The incidence of cancer and immunosuppressive disorders is increasing across the globe. Cancer patients frequently demand RBCs and platelet transfusions due to the adverse effects of chemotherapy, radiation, and bone marrow transplantation, which lead to anaemia and thrombocytopenia. As per the American Cancer Society, in the US, ~2 million new cancer cases were diagnoses in 2024, where estimated numbers of lymphoma were 89,190, Myeloma were 35,780, and Leukemia were 62,770. Most patients rely significantly on transfusions of blood components to cope with side effects and enhance quality of life.
Patients with immunosuppressed diseases such as HIV/AIDS, autoimmune diseases, and those on immunosuppressive therapy following organ transplantation need plasma-derived products such as immunoglobulins and clotting factors in order to enhance immune function and avert infections. In 2023, the Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that more than 39.9 million individuals were living with HIV worldwide, with many relying on blood components for survival.
According to GLOBOCAN estimates, the worldwide cancer prevalence is estimated to account for more than 28.4 million new cases per year by 2040, which will significantly boost demand for blood components in oncology treatment centers and hospitals. Furthermore, the rising population of older persons, who are more prone to cancer and immunosuppressive illnesses, drives demand for a secure and trustworthy blood supply.
These increasing health conditions highlight the paramount need for the constant provision of blood donation and high-tech blood component processing technologies. Healthcare institutions and blood banks are expanding their capability to keep up with this demand. Therefore, the increasing prevalence of cancer and immunosuppressive disorders boosts the donor blood component market growth.
Emerging economies, particularly in Southeast Asia, Latin America, and some regions in Africa, offer a strong growth opportunity for the donor blood component market. As healthcare infrastructure in these economies grows, investment in blood donation facilities is emerging as a strategic imperative. In Argentina, Brazil, and Mexico, voluntary donations voluntary donation programs have gained significant traction: Latin America received more than 9.2 million units in 2023, a 15.5% increase over 2020, with 56.8% of donations voluntary due to mobile drives and online campaigns. This growth represents the collaborative coordination of awareness campaigns and public–private alliances that have had on national blood systems. Similarly, in Indonesia, for instance, corporate donors such as Asian Agri initiated regional Blood Donation Weeks, accumulating hundreds of units from rural provinces. In June 2024, they engaged 414 donors and collected 287 units from three provinces, contributing to inventory and awareness. These private-sector cooperation enhances community trust and donor participation.
According to the WHO, the demand for blood products is projected to increase 5% each year in developing nations. To respond to the demand, the nations are focusing on the modernization of infrastructure, such as Indonesia's new plasma-fractionation factory and increased mobile blood collections in Africa. Technological utilization in the form of apheresis equipment, NAT testing, and automation processing is enhancing safety and public trust.
The convergence of growing medical demand, increasing voluntary donation, digital outreach, and regulatory reforms positions emerging markets for growth in donor blood services. Developments in these systems not only meet increasing clinical need but also catalyze long-term sustainability in the global donor blood component market.
Key segments that contributed to the derivation of the donor blood components market analysis are blood component, indication, application, age group, and end user.
The geographic scope of the donor blood components market report mainly focuses on five regions: North America, Asia Pacific, Europe, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the market in 2024. It is expected to continue its dominance in the global market during the forecast period. The US is the largest market for donor blood components in the world. According to the American Cancer Society, in 2022, ~1.9 million new cases of cancer were diagnosed in the country, and it caused ~0.61 million deaths. Cancer patients require regular blood transfusions during chemotherapy treatment. Chemotherapy and radiation therapies often lead to severe thrombocytopenia and neutropenia, necessitating platelet and plasma transfusions to prevent life-threatening bleeding and infections. According to The Leukemia & Lymphoma Society Facts and Statistics Overview, one person in the US is diagnosed with leukemia, lymphoma, or myeloma every 3 minutes. Also, ~456,481 people are living with leukemia. Leukemia affects bone marrow, reducing healthy blood cell production and causing anemia, which makes frequent transfusions of red cells, platelets, and plasma essential.
To meet the growing demand for blood components, blood banks and organizations, such as the American National Red Cross and the Association for the Advancement of Blood & Biotherapies, have intensified donor recruitment and blood collection efforts. As per the American National Red Cross, every two seconds, someone in the country needs blood or platelets for surgeries, cancer treatment, chronic illnesses, and traumatic injuries. ~29,000 units of RBCs, 5,000 units of platelets, and 6.500 units of plasma are needed every day in the nation. Per the same source, an estimated 6.8 million people donate blood each year in the US. This donation adds up to ~13.6 million units of whole blood and RBCs collected annually in the country. The American National Red Cross provides ~40% of the nation’s blood and blood cell components to donors, and ~16 million blood components are transfused annually in the US.
Furthermore, increasing demand for organ transplantation is likely to propel the demand for blood components. As per the data from the Organ Procurement and Transplantation Network (OPTN), the number of transplants performed in the country increased from 41,000 in 2021 to 48,149 in 2024. On average, the nation performed 132 transplants a day in 2024. During transplant surgeries, patients often experience substantial blood loss, requiring large quantities of blood to maintain stable circulation and support organ function. Recipients may need blood transfusions before and after surgery to manage anemia, boost recovery, and counter immune suppression therapies that can affect blood cell production.
The regional trends and factors influencing the Donor Blood Components Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Donor Blood Components Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 10.08 Billion |
| Market Size by | US$ 14.65 Billion in 2031 |
| Global CAGR (2025 - 2031) | 5.7% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Blood Component
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Donor Blood Components Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Donor Blood Components Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The donor blood components market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Key developments witnessed in the donor blood components market are as follows:
The "Donor Blood Components Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - Donor Blood Components Market
The rising prevalence of cancer and immunosuppressive diseases and increasing donor awareness are among the significant factors fueling the market growth.
North America dominated the market in 2024.
The rising demand for plasma-derived therapies is likely to emerge as a new growth trend in the market in the coming years.
Roswell Park Comprehensive Cancer Center, Policlinico of Milan, Vitalant, MD Anderson Cancer Center, The Johns Hopkins Hospital, The Royal Marsden, Gustave Roussy, Peter MacCallum Cancer Centre, Tata Memorial Hospital, Memorial Sloan Kettering Cancer Center are among the key players operating in the market.
The market is expected to register a CAGR of 5.7% during 2025–2031.
The market value is expected to reach US$ 14.64 billion by 2031.